Partex Announces Strategic Collaboration with Princeton Drug Discovery Ltd for Out-Licensing of PDD-87

Frankfurt, Germany, 20th February, 2025 – Partex is pleased to announce a strategic collaboration with Princeton Drug Discovery Ltd (PDD), a leading biotech company based in Princeton, NJ, USA, for the out-licensing of PDD-87. PDD-87 has unique mechanisms for treating aging-related diseases and cancers, discovered through structural modification of Dasatinib (Sprycel, Bristol Myers Squibb).

Under the agreement, Partex will leverage its proprietary AI-powered platform to expand the therapeutic potential of PDD-87. This advanced platform will help uncover new indications, optimize clinical positioning, and facilitate connections with prospective industry partners, ultimately enabling the successful out-licensing or sale of the asset.

“We are excited to collaborate with Princeton Drug Discovery Ltd and apply our AI-driven insights to unlock new possibilities for PDD-87,” said Dr. Frank Grams, Chief Commercial Officer of Partex NV. “This partnership exemplifies our commitment to accelerating innovation in drug development and bridging the gap between promising compounds and commercialization.”

Dr. Kan He, CEO and President of Princeton Drug Discovery Ltd, added, “We are thrilled to collaborate with Partex in advancing PDD-87. By leveraging their cutting-edge AI-powered platform, we aim to unlock the full potential of PDD-87, optimize its therapeutic applications, and accelerate its path to market. This partnership brings us one step closer to delivering innovative treatments to patients in need.

This collaboration aligns with Partex’s mission to integrate AI-driven intelligence with pharmaceutical R&D, enabling the efficient advancement of novel therapeutics. Both companies look forward to leveraging their combined expertise to bring innovative treatment options to patients worldwide.

About Partex
Partex is a pioneering AI-driven biopharmaceutical company dedicated to revolutionizing drug discovery and development. By harnessing cutting-edge AI technologies, Partex aims to accelerate the identification, development, and commercialization of breakthrough therapies.

Website:https://www.partex.io/

For more information or media inquiries, please contact:
Nidhi Duhan
Business Operations Manager
Partex NV
info@partex.io

About Princeton Drug Discovery Ltd
Princeton Drug Discovery Ltd is a biotech company focused on discovering and developing targeted therapies for unmet medical needs. Many existing drugs have dose-limiting toxicity, leading to treatment failure. The company specializes on discovering chemical variants of marketed drugs to enhance efficacy and significantly reduce toxicity.

For media inquiries, please contact:
Kan He
khe@princetondd.com
phone: 609-240-8333